Biotechnology company Elicera Therapeutics AB (publ) announced on Monday that its drug candidate ELC-100 has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for treating pancreatic neuroendocrine tumours.
ODD supports the development of treatments for rare diseases, with benefits including tax credits for US clinical trials and potential fee waivers for marketing approval. In addition, ODD provides up to seven years of market exclusivity upon approval.
ELC-100 is based on an oncolytic virus and targets neuroendocrine cancer cells selectively. Elicera is currently conducting a Phase I/II trial to determine the maximum tolerated dose (MTD) and assess safety. The company completed patient recruitment for the trial's first part in fall 2024. Final data from this phase is expected in mid-2025.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024